Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies
· The trial is now fully recruited with a total of 33 patients enrolled with 30 patients in the full dose ONCOS-102 and durvalumab combination in the colorectal cancer cohort Oslo, Norway, 17 June 2021 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the ONCOS-102 and durvalumab trial in patients with advanced peritoneal malignancies has completed enrollment in the colorectal cancer cohort. This phase 1/2 trial investigates the safety, biologic and anti-tumor activity of